Form 8-K - Current report:
SEC Accession No. 0001193125-23-042033
Filing Date
2023-02-17
Accepted
2023-02-17 16:31:04
Documents
12
Period of Report
2023-02-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d464691d8k.htm   iXBRL 8-K 37178
  Complete submission text file 0001193125-23-042033.txt   159691

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vnda-20230216.xsd EX-101.SCH 2890
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20230216_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20230216_pre.xml EX-101.PRE 11288
6 EXTRACTED XBRL INSTANCE DOCUMENT d464691d8k_htm.xml XML 3366
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 23643129
SIC: 2834 Pharmaceutical Preparations